

CLAIMS

1. An anti-Sortilin antibody, or an antigen-binding fragment thereof, selected from the group consisting of antibodies (1)-(21);

Antibody (1) is characterized by:

- a. a light chain variable domain L-CDR1 comprising **SEQ ID NO:1**;
- b. a light chain variable domain L-CDR 2 comprising **SEQ ID NO:2**;
- c. a light chain variable domain L-CDR 3 comprising **SEQ ID NO:3**;
- d. a heavy chain variable domain H-CDR 1 comprising **SEQ ID NO:4**;
- e. a heavy chain variable domain H-CDR 2 comprising **SEQ ID NO:5**; and
- f. a heavy chain variable domain H-CDR 3 comprising **SEQ ID NO:6**.

Antibody (2) is characterized by:

- a. a light chain variable domain L-CDR1 comprising **SEQ ID NO:9**;
- b. a light chain variable domain L-CDR 2 comprising **SEQ ID NO:10**;
- c. a light chain variable domain L-CDR 3 comprising **SEQ ID NO:11**;
- d. a heavy chain variable domain H-CDR 1 comprising **SEQ ID NO:12**;
- e. a heavy chain variable domain H-CDR 2 comprising **SEQ ID NO:13**; and
- f. a heavy chain variable domain H-CDR 3 comprising **SEQ ID NO:14**.

Antibody (3) is characterized by:

- a. a light chain variable domain L-CDR1 comprising **SEQ ID NO:17**;
- b. a light chain variable domain L-CDR 2 comprising **SEQ ID NO:18**;
- c. a light chain variable domain L-CDR 3 comprising **SEQ ID NO:19**;
- d. a heavy chain variable domain H-CDR 1 comprising **SEQ ID NO:20**;
- e. a heavy chain variable domain H-CDR 2 comprising **SEQ ID NO:21**;
and
- f. a heavy chain variable domain H-CDR 3 comprising **SEQ ID NO:22**.

Antibody (4) is characterized by:

- a. a light chain variable domain L-CDR1 comprising **SEQ ID NO:25**;
- b. a light chain variable domain L-CDR 2 comprising **SEQ ID NO:26**;